Upcoming Webinar | March 31, 2026 | 10:00 AM EST / 4:00 PM CET

Lessons From the Last Decade of Preclinical Oncology Projects Using Humanized Mice

About the webinar:

The availability and versatility of robust human immune system mouse models are poised to increase preclinical predictiveness of complex modalities, including biologics and cell and gene therapies. Drawing on more than a decade of experience and over a thousand oncology studies, we present a modular design framework for customizing preclinical projects. This approach guides the selection of mouse strains aligned with mechanism-of-action requirements and tumor models informed by TIL composition and target expression profiling, ensuring biologically relevant drug assessment while highlighting the flexibility of model humanization for program-specific translational strategies.

Key Takeaways:

Advantages of using humanized immune system (HIS) mouse models in preclinical oncology
How to select and customize the appropriate HIS model for your oncology study
Study design considerations, including tumor model selection based on target expression and TIL profile
Choosing between subcutaneous and orthotopic engraftment sites
Simultaneously derisking cytokine release syndrome (CRS) while assessing efficacy

Taconic Biosciences and TransCure bioServices: Humanized Research to Support Translational Decisions

Taconic's acquisition of TransCure bioServices brings humanized model generation and in vivo translational studies together under one scientific platform. Researchers can now work with a single partner to design, execute, and interpret studies in humanized mouse systems—reducing operational complexity while improving data continuity and interpretability.

Visit the platform and learn how we can advance your preclinical research.

Secure Your Spot

Meet the Team

Speaker:

Dan Georgess, PhD

Chief Scientific Officer | TransCure bioServices

Dan Georgess is Chief Scientific Officer at TransCure bioServices, a Taconic Biosciences™ company and leading CRO delivering advanced preclinical solutions to global pharma, biotech, and academic partners. With 18 years of experience, Dan specializes in building integrated in vitro, ex vivo, and in vivo pipelines for oncology, metabolic, and autoimmune disease research. He earned his PhD from École normale supérieure de Lyon and completed postdoctoral training at Johns Hopkins University School of Medicine. He later served as Principal Investigator at the Lebanese American University, where he founded and led the Breast Cancer Invasion and Metastasis Cluster. At TransCure, Dan drives the development of translational preclinical strategies enabling drug developers to identify novel disease biology and evaluate efficacy, PK/PD, mechanism of action, and safety of next-generation therapeutic candidates.

Moderator:

Philip Dubé, PhD

Director, Scientific Marketing | Taconic Biosciences

Dr. Philip Dubé is the Director of Scientific Marketing at Taconic Biosciences with over 18 years of experience in rodent model use. He specializes in mouse models for immunology, oncology, immuno-oncology, and inflammatory bowel disease (IBD). Dr. Dubé earned his Ph.D. in physiology and an Honors B.Sc. in pharmacology from the University of Toronto. He completed postdoctoral fellowships in IBD research at Vanderbilt University and Children’s Hospital Los Angeles and has served as an Institutional Animal Care and Use Committee member.